Breakthrough Invasive Candidiasis in Patients on Micafungin
نویسندگان
چکیده
منابع مشابه
Breakthrough Invasive Candidiasis in Children
165. Outcomes Comparing Initial Short vs Long Course Echinocandin Therapy in Patients with Candidemia Caused by Fluconazole Susceptible Strains Jennifer L. Small-Saunders, MD, PhD; Angela Loo, PharmD BCPS (AQ-ID); Deborah Theodore, MD; Amrita Singh, PharmD; Magdalena Sobieszczyk, MD, MPH and Christine J. Kubin, PharmD BCPS (AQ-ID); Medicine, Columbia University Medical Center, New York, New Yor...
متن کاملMicafungin in the treatment of invasive candidiasis and invasive aspergillosis
Micafungin is an echinocandin antifungal agent available for clinical use in Japan, Europe, and the United States. Through inhibition of β-1,3-glucan production, an essential component of the fungal cell wall, micafungin exhibits potent antifungal activity against key pathogenic fungi, including Candida and Aspergillus species, while contributing minimal toxicity to mammalian cells. This activi...
متن کاملMicafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
BACKGROUND In critically ill patients the incidence of invasive fungal infections caused by Candida spp. has increased remarkably. Echinocandins are recommended as initial treatment for invasive fungal infections. The safety and efficacy of micafungin compared to caspofungin is similar, but no comparison is made between anidulafungin and micafungin concerning safety and efficacy. We therefore p...
متن کاملPharmacokinetics of Micafungin in Adult Patients with Invasive Candidiasis and Candidemia
Micafungin is an efficacious and well-tolerated echinocandin with in vitro and in vivo activity against a broad range of Candida species. The objective of this randomized, double-blind study was to examine the pharmacokinetic parameters of micafungin and its metabolites in a subset of adult patients with invasive candidiasis or candidemia. The study was conducted at 27 sites in four countries, ...
متن کاملBreakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
BACKGROUND Micafungin is a newly approved antifungal agent in the echinocandin class that is active against Candida species and Aspergillus species. However, this agent has limited activity against a number of fungi, including Trichosporon species. We describe 4 patients who developed disseminated trichosporonosis during the use of micafungin. No cases of trichosporonosis had been seen in the 2...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Microbiology
سال: 2010
ISSN: 0095-1137,1098-660X
DOI: 10.1128/jcm.02390-09